SHALANDRIA SIMS: Open Payments
NPI 1235683442 · ATLANTA, GA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$342 in 16 payments from 8 companies in 2025. Trend: 2023 $33 · 2024 $58 · 2025 $342
Food & beverage: $342
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 5 | $85 |
| Braeburn Inc. | 3 | $84 |
| Indivior Inc. | 2 | $39 |
| Collegium Pharmaceutical, Inc. | 2 | $34 |
| Alkermes, Inc. | 1 | $32 |
| Vanda Pharmaceuticals Inc. | 1 | $28 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $25 |
| ABBVIE INC. | 1 | $15 |
Products named: CAPLYTA, BRIXADI, SUBLOCADE, VIVITROL, HETLIOZ, TRINTELLIX, Belbuca, VRAYLAR.
Industry payments across GA — which companies pay providers there.
